What is Arcutis Biotherapeutics, Inc.'s market cap?

Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of $3.5B and trades on NASDAQ.

What is Arcutis Biotherapeutics, Inc.'s revenue and profitability?

Arcutis Biotherapeutics, Inc. generated $415.6M in trailing twelve-month revenue with a net loss of $44.8M, representing a net margin of -13.9%. Gross margin stands at 90.9%, with free cash flow of -$31.3M. These figures are based on the Q1 2026 filing.

Who are Arcutis Biotherapeutics, Inc.'s competitors?

Arcutis Biotherapeutics, Inc.'s key competitors include Incyte Corporation, Amgen Inc., Pfizer Inc., and others. These companies compete in similar markets and product categories.

Who does Arcutis Biotherapeutics, Inc. partner with?

Arcutis Biotherapeutics, Inc.'s notable partners include Kowa Pharmaceuticals America, Inc., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Sato Pharmaceutical Co., Ltd., and others.

What subsidiaries does Arcutis Biotherapeutics, Inc. have?

Arcutis Biotherapeutics, Inc.'s subsidiaries include Ducentis BioTherapeutics LTD.

Where is Arcutis Biotherapeutics, Inc. headquartered?

Arcutis Biotherapeutics, Inc. is headquartered in United States of America and employs approximately 296 people. It has been publicly traded since 2020.

Arcutis Biotherapeutics, Inc.

ARQT

Market cap

$3.48B+100%

Revenue$415.6M+95.3%

Net income-$44.8M+68.0%

Free cash flow-$31.3M+81.4%

EPS (diluted)-$0.36+68.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$105.4MBeat by $1.7M EPS-$0.09Miss by $0.07

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$118.9M

EPS estimate$0.09

Financials

Q1 2026

Income statement

See full

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Balance sheet

See full

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Cash flow

See full

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Valuation & ratios

Valuation

See full

Market cap$3.42B+100%

Enterprise value$3.5B+95.7%

P/S8.2×+1.6×

Profitability

See full

Gross margin90.9%+2.5pp

Returns & leverage

See full

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Segments

By segment

See full

Reportable Segment$105.4M+60.1%

Competitors

By market cap

Amgen$202.95B+23.1%

Pfizer$139.86B-0.8%

Incyte$23.5B+73.0%

Arcutis Biotherapeutics, Inc.$3.4B+93.1%

PVL

Palvella Therapeutics$2.0B+364%

Zura Bio Limited$496.8M+390%

Verrica Pharmaceuticals Inc.$86.2M+41.1%

Sonoma Pharmaceuticals, Inc.$5.5M-2.9%

By revenue growth

Arcutis Biotherapeutics, Inc.+95.3%

Incyte+26.9%

Amgen+9.1%

Pfizer+1.4%

By net margin

PVL

Palvella Therapeutics71.68%—

Incyte27.71%+8.7pp

Amgen20.96%+3.6pp

Pfizer15.65%+6.3pp

Arcutis Biotherapeutics, Inc.-13.94%+55.0pp

Profile

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of topical and systemic treatments for immune-mediated dermatological diseases. The company leverages a drug development platform focused on validated biological targets to address unmet needs in conditions like psoriasis, atopic dermatitis, and seborrheic dermatitis. Its core value proposition lies in providing steroid-free, once-daily therapies suitable for chronic use across all body areas.

Competitive position

Arcutis is a leading innovator in non-steroidal topical treatments, holding a significant competitive advantage through its proprietary PDE4 inhibitor formulations and long-term patent exclusivity.

GeographiesUnited States, Canada, Greater China, Southeast Asia, Japan

Customer segmentsMedical professionals, Pediatric patients, Adult patients

Business modelR&D-based drug development, Direct product sales, Licensing and royalties

SuppliersPharmaceutical ingredient suppliers, Contract manufacturing organizations, Clinical research organizations

CustomersWholesale drug distributors, Pharmacies, Hospitals, Specialty clinics

CountryUnited States of America

Listed2020

Employees296.0

CEOTodd Franklin Watanabe

SectorHealthcare

IndustryBiotechnology

Websitearcutis.com

FilingsSEC EDGAR

Ask your AI about Arcutis Biotherapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s market cap?: Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of $3.5B and trades on NASDAQ.
What is Arcutis Biotherapeutics, Inc.'s revenue and profitability?: Arcutis Biotherapeutics, Inc. generated $415.6M in trailing twelve-month revenue with a net loss of $44.8M, representing a net margin of -13.9%. Gross margin stands at 90.9%, with free cash flow of -$31.3M. These figures are based on the Q1 2026 filing.
Who are Arcutis Biotherapeutics, Inc.'s competitors?: Arcutis Biotherapeutics, Inc.'s key competitors include Incyte Corporation, Amgen Inc., Pfizer Inc., and others. These companies compete in similar markets and product categories.
Who does Arcutis Biotherapeutics, Inc. partner with?: Arcutis Biotherapeutics, Inc.'s notable partners include Kowa Pharmaceuticals America, Inc., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Sato Pharmaceutical Co., Ltd., and others.
What subsidiaries does Arcutis Biotherapeutics, Inc. have?: Arcutis Biotherapeutics, Inc.'s subsidiaries include Ducentis BioTherapeutics LTD.
Where is Arcutis Biotherapeutics, Inc. headquartered?: Arcutis Biotherapeutics, Inc. is headquartered in United States of America and employs approximately 296 people. It has been publicly traded since 2020.